ArticleFrontiers in pharmacology2026
Formulation and characterization of agar based aerogels as potential implantable controlled drug delivery system.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Agar-based aerogels have emerged as promising candidates for implantable drug delivery systems due to their tunable porosity, mechanical properties, and biocompatibility. Methods: Agar aerogels were prepared at varying concentrations (2, 2.5, 3, and 3.5% w/v) and loaded with caffeine as a model drug using preloading and post-loading techniques. The formulations were characterized for mechanical strength, porosity, swelling behavior, drug content distribution, and in vitro release profiles. Raman mapping and HPLC analysis were employed to evaluate drug distribution and quantification. Results: Increasing agar concentration significantly enhanced mechanical strength while reducing porosity and swelling capacity. Preloaded aerogels demonstrated improved mechanical stability, whereas post-loaded aerogels exhibited reduced strength with increasing loading volume. Drug distribution was more homogeneous at lower agar concentrations and moderate drug loadings. All formulations exhibited biphasic release profiles, with an initial burst release followed by sustained release, influenced by agar concentration, drug loading, and loading method. Discussion: Optimized formulations, particularly preloaded aerogels with 5% caffeine and post-loaded aerogels with 1% caffeine at controlled volumes, demonstrated desirable mechanical and release characteristics. These findings highlight the potential of agar-based aerogels as versatile and tunable systems for localized controlled drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.